Search Results | Diabetes | American Diabetes Association

1-5 of 5

Sort by

Sort Order Select

Meeting Abstracts

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, DAVID CHERNEY, BERNARD CHARBONNEL, DARREN K. MCGUIRE, FRANCESCO COSENTINO, WEICHUNG J. SHIH, JIE LIU, ROBERT FREDERICH, JAMES P. MANCUSO, ANNASWAMY RAJI, IRA GANTZ

Diabetes 2021;70(Supplement_1):786-P

DOI: https://doi.org/10.2337/db21-786-P

Published: 01 June 2021

View article

Meeting Abstracts

1232-P: Predictors of ß-Cell Function Changes: Pooled Analysis from Phase 3 Ertugliflozin Studies

SILVINA GALLO, ANNASWAMY RAJI, ROBERTO A. CALLE, MISOO C. ELLISON, CHRISTIAN MEYER

Diabetes 2019;68(Supplement_1):1232-P

DOI: https://doi.org/10.2337/db19-1232-P

Published: 01 June 2019

View article

Meeting Abstracts

1119-P: Efficacy and Safety of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in People ≥65 Years Old with T2D

ANNASWAMY RAJI, ZHI JIN XU, RAYMOND L. LAM, KEITH D. KAUFMAN, SAMUEL S. ENGEL

Diabetes 2019;68(Supplement_1):1119-P

DOI: https://doi.org/10.2337/db19-1119-P

Published: 01 June 2019

View article

Meeting Abstracts

A1C Goal Attainment with Initial Dual Therapy with Metformin (MET)/Sitagliptin (SITA) Compared with Met Monotherapy—Impact of Baseline A1C and Target A1C

ANNASWAMY RAJI, MISOO C. ELLISON, RAYMOND L.H. LAM, EDWARD A. O'NEILL, SAMUEL S. ENGEL

Diabetes 2018;67(Supplement_1):1143-P

DOI: https://doi.org/10.2337/db18-1143-P

Published: 01 July 2018

View article

Meeting Abstracts

Safety and Efficacy of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in Subjects with T2D, Mild Renal Impairment, and Inadequate Glycemic Control on Metformin (MET) ± a Sulfonylurea (SU)

RUSSELL S. SCOTT, JERRY D. MORGAN, ZACHARY ZIMMER, RAYMOND L.H. LAM, EDWARD A. O'NEILL, KEITH D. KAUFMAN, SAMUEL S. ENGEL, ANNASWAMY RAJI

Diabetes 2018;67(Supplement_1):1142-P

DOI: https://doi.org/10.2337/db18-1142-P

Published: 01 July 2018

View article

NARROW

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

1232-P: Predictors of ß-Cell Function Changes: Pooled Analysis from Phase 3 Ertugliflozin Studies

1119-P: Efficacy and Safety of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in People ≥65 Years Old with T2D

A1C Goal Attainment with Initial Dual Therapy with Metformin (MET)/Sitagliptin (SITA) Compared with Met Monotherapy—Impact of Baseline A1C and Target A1C

Safety and Efficacy of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in Subjects with T2D, Mild Renal Impairment, and Inadequate Glycemic Control on Metformin (MET) ± a Sulfonylurea (SU)

Email alerts

Journals

Books

News

Other

About

Resources

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

1232-P: Predictors of ß-Cell Function Changes: Pooled Analysis from Phase 3 Ertugliflozin Studies

1119-P: Efficacy and Safety of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in People ≥65 Years Old with T2D

A1C Goal Attainment with Initial Dual Therapy with Metformin (MET)/Sitagliptin (SITA) Compared with Met Monotherapy—Impact of Baseline A1C and Target A1C

Safety and Efficacy of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in Subjects with T2D, Mild Renal Impairment, and Inadequate Glycemic Control on Metformin (MET) ± a Sulfonylurea (SU)

Email alerts

Journals

Books

News

Other

About

Resources

This Feature Is Available To Subscribers Only